Skip to main content

Harmony Biosciences Holdings, Inc.

corporate_fare Company Profile

Harmony Biosciences Holdings, Inc.

HRMY·NASDAQ·Life Sciences·CIK 0001802665

The company is a neuroscience company focused on rare neurological diseases, with a portfolio covering sleep/wake, rare epilepsy, and neurobehavioral conditions. Its lead product is WAKIX® (pitolisant), a therapy that enhances histamine signaling in the brain by binding to H3 receptors. The company acquired exclusive commercialization rights for pitolisant from Bioprojet Société Civile de Recherche ("Bioprojet") in July 2017. WAKIX was initially approved by the FDA in 2019 for excessive daytime sleepiness ("EDS") in adult narcolepsy patients, followed by approvals for cataplexy in adult patients in 2020, EDS in pediatric patients six years and older in 2024, and cataplexy in pediatric patients six years and older in 2026. WAKIX is the only FDA-approved narcolepsy treatment not scheduled as a controlled substance by the U.S. Drug Enforcement Administration ("DEA"). The company is also exploring pitolisant in late-stage clinical programs for idiopathic hypersomnia ("IH"), Prader-Willi syndrome ("PWS"), and myotonic dystrophy type 1 ("DM1"). In July 2022, the company obtained exclusive rights from Bioprojet to manufacture, develop, and commercialize next-generation pitolisant-based products in the United States and Latin America, including pitolisant Gastro-Resistant ("Pitolisant GR") and pitolisant High-Dose ("Pitolisant HD"), both currently in clinical development. In April 2024, the company expanded into orexin science through a sublicense agreement with Bioprojet for BP1.15205, an orexin 2 receptor agonist in preclinical development for narcolepsy and other potential indications.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for HRMY at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Harmony Biosciences Reports Strong 2025 Results, Secures Pediatric Cataplexy Approval for WAKIX, and Advances Pipeline
  • Harmony Biosciences Reports Strong 2025 Revenue, Reiterates 2026 Guidance, Despite Q4 Profit Decline
  • Harmony Biosciences Guides WAKIX to Blockbuster Status with $1B+ 2026 Revenue, Advances Robust Late-Stage Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$868.45M
Net Income
$158.69M
Diluted EPS
$2.71
Op. Cash Flow
$348.2M
Free Cash Flow
$347.89M
Gross Profit
$670.11M
Operating Income
$208.47M
Cash & Equivalents
$752.5M
Total Debt
$163.66M
Debt / Equity
0.19×
Net Margin
18.3%
Shares Outstanding
57.73M sh
Source: 10-K · filed 2026-02-24 · accession 0001104659-26-018859
$32.43 -0.49% today
52-week range · as of 2026-11-04 $25.9 – $43.49
Market cap
$1.91B
Volume
582.6K (0.5× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HRMY - Filings & News (Page 2)

HRMY
Feb 24, 2026, 8:16 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $26.41
Real-time Price: $32.43 info
Change: +$6.02 (+23%) info
Market Cap: $1.914B info
HRMY
Feb 24, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.41
Real-time Price: $32.43 info
Change: +$6.02 (+23%) info
Market Cap: $1.914B info
HRMY
Jan 12, 2026, 8:20 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $38.44
Real-time Price: $32.43 info
Change: -$6.01 (-16%) info
Market Cap: $1.914B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets